Analysts think GKOS stock price could increase by 3%
Dec 25, 2024, 12:25 PM
6.61%
What does GKOS do
Glaukos, based in Aliso Viejo, California, specializes in innovative therapies for glaucoma and retinal diseases, employing 907 staff since its IPO on June 25, 2015. Their products include micro-invasive devices and dropless treatments to reduce intraocular pressure.
15 analysts think GKOS stock price will increase by 3.20%. The current median analyst target is $156.06 compared to a current stock price of $151.22. The lowest analysts target is $121.20 and the highest analyst target is $194.25.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
